Barclays Cuts LivaNova (NASDAQ:LIVN) Price Target to $56.00

LivaNova (NASDAQ:LIVN) had its target price cut by Barclays from $58.00 to $56.00 in a research report report published on Friday morning,Benzinga reports. They currently have an equal weight rating on the stock.

A number of other research analysts have also weighed in on LIVN. Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 26th. Mizuho cut their price objective on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. The Goldman Sachs Group cut their price objective on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. Finally, Needham & Company LLC cut their price objective on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, LivaNova presently has an average rating of “Moderate Buy” and an average price target of $61.17.

LivaNova Stock Down 2.1 %

LivaNova stock opened at $39.17 on Friday. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of 93.26 and a beta of 1.10. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. LivaNova has a fifty-two week low of $38.91 and a fifty-two week high of $64.47. The firm has a fifty day moving average price of $46.79 and a two-hundred day moving average price of $49.32.

Insider Buying and Selling

In related news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now owns 7,522 shares of the company’s stock, valued at $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. raised its position in LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after purchasing an additional 219 shares in the last quarter. Sterling Capital Management LLC grew its stake in LivaNova by 800.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after buying an additional 1,441 shares during the last quarter. Central Pacific Bank Trust Division grew its stake in LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after buying an additional 720 shares during the last quarter. Captrust Financial Advisors bought a new stake in LivaNova during the third quarter worth about $217,000. Finally, Sanctuary Advisors LLC bought a new stake in LivaNova during the third quarter worth about $219,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.